journal
https://read.qxmd.com/read/38889066/mindfulness-as-a-therapeutic-option-for-obsessive-compulsive-disorder
#1
JOURNAL ARTICLE
Andreas Reis, Marlon Westhoff, Hicham Quintarelli, Stefan G Hofmann
INTRODUCTION: Obsessive-compulsive disorder (OCD) is a prevalent mental health issue characterized by intrusive thoughts (obsessions) and repetitive behaviors (compulsions) that can cause significant life impairment. Despite cognitive-behavioral therapy (CBT) being the most effective treatment, some individuals experience insufficient symptom reduction or relapse. AREAS COVERED: This special report explores the potential of mindfulness-based interventions as complementary treatments for OCD, examining the specific techniques used and their practical application...
June 18, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38881379/rethinking-the-role-of-trazodone-in-the-different-depressive-dimensions
#2
JOURNAL ARTICLE
Isabella Berardelli, Andrea Amerio, Francesco Bartoli, Alessandro Cuomo, Giacomo Deste, Laura Orsolini, Gaia Sampogna, Maurizio Pompili
INTRODUCTION: The efficacy of trazodone for several psychopathologic dimensions of depression has been shown in the literature. Trazodone has been widely used in some clinical contexts (e.g. for insomnia and depression in the elderly). However, the role of trazodone in several aspects of depression is not well known. AREA COVERED: Eight experts from academic and medical centers across Italy met to identify the difficulties and barriers faced in daily clinical practice in the assessment and management of major depressive disorder and how the use of trazodone could address some unmet needs...
June 17, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38879828/gantenerumab-for-early-alzheimer-s-disease-a-systematic-review-and-meta-analysis
#3
REVIEW
Artur Menegaz de Almeida, Marianna Leite, Lucca Moreira Lopes, Pedro Gomes Lima, Maria Luísa Siegloch Barros, Samuel Rocha Pinheiro, Ítalo Andrade, Patrícia Viana, Victória Morbach, Gabriel Marinheiro, Ricardo de Oliveira, Agostinho C Pinheiro
INTRODUCTION: Gantenerumab is a monoclonal antibody targeting amyloid β protein (Aβ) in early Alzheimer's disease (AD). The authors sought to evaluate gantenerumab safety and efficacy in early AD patients. METHODS: MEDLINE, Embase, and Cochrane databases were systematically searched until 2 December 2023. Data were examined using the Mantel-Haenszel method and 95% confidence intervals (CIs). Meta-regression analysis was conducted to evaluate a possible link between baseline Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) and amyloid-related imaging abnormalities (ARIA) at follow-up...
June 16, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38879827/re-evaluating-the-prognosis-of-schizophrenia-tackling-the-issue-of-inadequate-treatment
#4
EDITORIAL
Ofer Agid
No abstract text is available yet for this article.
June 16, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38879824/imaging-protocols-for-non-traumatic-spinal-cord-injury-current-state-of-the-art-and-future-directions
#5
REVIEW
Abdullah H Ishaque, Mohammed Ali Alvi, Karlo Pedro, Michael G Fehlings
INTRODUCTION: Non-traumatic spinal cord injury (NTSCI) is a term used to describe damage to the spinal cord from sources other than trauma. Neuroimaging techniques such as computerized tomography (CT) and magnetic resonance imaging (MRI) have improved our ability to diagnose and manage NTSCIs. Several practice guidelines utilize MRI in the diagnostic evaluation of traumatic and non-traumatic SCI to direct surgical intervention. AREAS COVERED: The authors review practices surrounding the imaging of various causes of NTSCI as well as recent advances and future directions for the use of novel imaging modalities in this realm...
June 16, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38875186/why-does-exposure-based-therapy-fail-in-some-individuals-with-obsessive-compulsive-disorder
#6
EDITORIAL
Benedikt Reuter, Annemarie Miano, Josepha Wassermann, Björn Elsner
No abstract text is available yet for this article.
June 14, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38870050/an-update-on-pharmacotherapy-for-trigeminal-neuralgia
#7
REVIEW
Joseph V Pergolizzi, Jo Ann LeQuang, Salah N El-Tallawy, Morgan Wagner, Rania S Ahmed, Giustino Varrassi
INTRODUCTION: Trigeminal neuralgia is a rare condition that can be effectively treated by carbamazepine or oxcarbazepine but these older drugs are associated with dose-dependent and potentially treatment-limiting adverse effects. Third-generation anticonvulsants, new calcitonin gene-related peptide blockers for migraine, and older drugs such as ketamine and cannabinoids may be promising adjuvants or monotherapeutic options. AREAS COVERED: The new drugs, their presumed mechanisms of action, safety and efficacy are discussed herein...
June 13, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38870024/preferences-and-perceptions-of-617-migraine-patients-on-acute-and-preventive-migraine-treatment-attributes-and-clinical-trial-endpoints
#8
JOURNAL ARTICLE
Michail Vikelis, Dimitrios Rikos, Andreas A Argyriou, Pinelopi Papachristou, Dimitrios Rallis, Theodoros Karapanayiotides, Andreas Galanopoulos, Konstantinos Spingos, Nikolaos Dimisianos, Emmanouil Giakoumakis, Periklis Zavridis, Konstantinos Notas, George S Vlachos, Panagiotis Soldatos, Konstantinos Bilias, Georgia Xiromerisiou, Jobst Rudolf, Emmanouil V Dermitzakis, Alan M Rapoport
BACKGROUND: To identify the preferences and perceptions of migraine patients for acute and preventive treatment options and to investigate which treatment outcomes are the most important. DESIGN AND METHODS: The authors performed a choice-format survey in a cohort of migraine patients from Greece and Cyprus. A self-administered questionnaire developed in collaboration with the Greek Society of Migraine Patients was used. RESULTS: Questionnaires were collected from 617 migraine patients...
June 13, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38864423/an-overview-of-the-efficacy-and-safety-of-brexpiprazole-for-the-treatment-of-schizophrenia-in-adolescents
#9
REVIEW
Chesika J Crump, Hagar Abuelazm, Kirolos Ibrahim, Shaishav Shah, Rif S El-Mallakh
INTRODUCTION: Onset of psychotic symptoms occurs prior to age 19 in 39% of patients with schizophrenia. There are limited approved treatment options for adolescents with schizophrenia. Brexpiprazole was approved by the United States Food and Drug Administration (FDA) for treatment of schizophrenia in adolescents in 2022. AREAS COVERED: Extrapolation of adult data to youth and use of pharmacologic modeling coupled with open long-term safety data were used by the FDA to approve brexpiprazole for adolescent schizophrenia...
June 12, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38860467/phase-specific-strategies-and-interventions-to-enhance-medication-adherence-across-different-phases-in-adhd-a-systematic-review-and-meta-analysis
#10
REVIEW
Muhammad Umair Khan, Syed Shahzad Hasan
INTRODUCTION: This systematic review and meta-analysis assessed the characteristics, types, and impact of interventions to improve adherence to attention-deficit hyperactivity disorder (ADHD) medications within the context of the three phases of adherence, namely, initiation, implementation, and discontinuation. METHODS: PubMed, Psychological Information Database, Embase, International Pharmaceutical Abstracts, and Google Scholar were systematically searched for relevant trials using appropriate search terms...
June 11, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38814926/developments-in-the-prediction-of-cognitive-changes-following-deep-brain-stimulation-in-persons-with-parkinson-s-disease
#11
REVIEW
Alexander I Tröster
INTRODUCTION: Deep brain stimulation (DBS) is an effective treatment for Parkinson's disease (PD) motor symptoms that improves function and quality of life in appropriately selected patients. Because mild to moderate cognitive declines can follow DBS and impact quality of life in a minority of patients, an important consideration involves the cognitive deficit and its prediction. AREAS COVERED: The author briefly summarizes cognitive outcomes from DBS and reviews in more detail the risks/predictors of post-DBS cognitive dysfunction by mainly focusing on work published between 2018 and 2024 and using comprehensive neuropsychological (NP) evaluations...
May 30, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38814860/identification-and-treatment-of-surgically-remediable-causes-of-infantile-epileptic-spasms-syndrome
#12
REVIEW
Emma Macdonald-Laurs, Winston Dzau, Aaron E L Warren, Matthew Coleman, Cristina Mignone, Sarah E M Stephenson, Katherine B Howell
INTRODUCTION: Infantile epileptic spasms syndrome (IESS) is a common developmental and epileptic encephalopathy with poor long-term outcomes. A substantial proportion of patients with IESS have a potentially surgically remediable etiology. Despite this, epilepsy surgery is underutilized in this patient group. Some surgically remediable etiologies, such as focal cortical dysplasia and malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE), are under-diagnosed in infants and young children...
May 30, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38805342/challenges-in-the-treatment-of-dysthymia-a-narrative-review
#13
REVIEW
Livia Mathias, Laiana A Quagliato, Mauro G Carta, Antonio E Nardi, Elie Cheniaux
INTRODUCTION: Despite its milder severity, the chronic nature of dysthymia leads to significant impairments and functional limitations. The treatment of dysthymia has received considerably less research attention compared to major depressive disorder (MDD). AREAS COVERED: The authors have conducted a comprehensive review on the treatment of dysthymia. Their primary objective was to identify therapeutic options that have demonstrated genuine efficacy. To do this, they searched the PubMed database, without any time restrictions, to retrieve original studies...
May 28, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38803205/risk-factors-and-disease-associations-in-people-living-with-idiopathic-intracranial-hypertension
#14
REVIEW
Olivia Potter, Vaishnavi Menon, Susan P Mollan
INTRODUCTION: Idiopathic intracranial hypertension is a neurological condition characterized by a raised intracranial pressure and papilledema, leading to chronic headaches and visual disturbances. By recognizing modifiable risk factors and deploying evidence-based interventions, healthcare providers have the potential to mitigate the burden of the disease and improve patient outcomes. AREAS COVERED: It is well known that the condition occurs in predominantly pre-menopausal females who live with obesity particularly in the context of recent weight gain...
May 27, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38800947/the-challenges-and-opportunities-related-to-the-therapeutic-use-of-music-in-psychiatry
#15
EDITORIAL
Hubertus Himmerich, Annie Heiderscheit
No abstract text is available yet for this article.
May 27, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38738544/the-management-of-sleep-disturbances-in-children-with-attention-deficit-hyperactivity-disorder-adhd-an-update-of-the-literature
#16
REVIEW
Samuele Cortese, Guilherme Fusetto Veronesi, Alessandra Gabellone, Anna Margari, Lucia Marzulli, Emilia Matera, Maria Giuseppina Petruzelli, Francesco Maria Piarulli, Fabio Tarantino, Alessio Bellato, Valeria Parlatini, Ebba Du Rietz, Henrik Larsson, Samantha Hornsey, Cathy Hill, Lucia Margari
INTRODUCTION: Sleep disorders represent an important comorbidity in individuals with ADHD. While the links between ADHD and sleep disturbances have been extensively investigated, research on the management of sleep disorders in individuals with ADHD is relatively limited, albeit expanding. AREAS COVERED: The authors searched PubMed, Medline, PsycInfo, Embase+Embase Classic, Web of Sciences databases, and clinicaltrials.gov up to 4 January 2024, for randomized controlled trials (RCTs) of any intervention for sleep disorders associated with ADHD...
May 13, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38720652/tackling-internet-gaming-disorder-what-are-the-challenges-in-its-treatment
#17
EDITORIAL
Kristyn Zajac, Meredith K Ginley, Lourah M Kelly, Jessica N Flori, Rory A Pfund
No abstract text is available yet for this article.
May 9, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38713485/radiosurgical-thalamotomy-for-essential-tremor-state-of-the-art-current-challenges-and-future-directions
#18
REVIEW
Christian Iorio-Morin, David Mathieu, Andrea Franzini, Mojgan Hodaie, Samuelle-Arianne Villeneuve, Andréanne Hamel, Andres M Lozano
INTRODUCTION: Essential tremor (ET) is the most frequent movement disorder, affecting up to 5% of adults > 65 years old. In 30-50% of cases, optimal medical management provides insufficient tremor relief and surgical options are considered. Thalamotomy is a time-honored intervention, which can be performed using radiofrequency (RF), stereotactic radiosurgery (SRS), or magnetic resonance-guided focused ultrasounds (MRgFUS). While the latter has received considerable attention in the last decade, SRS has consistently been demonstrated as an effective and well-tolerated option...
May 7, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38655598/dihydroergotamine-mesylate-nasal-spray-an-acute-treatment-option-for-migraine-in-adults
#19
REVIEW
Marcello Silvestro, Ilaria Orologio, Alessandro Tessitore, Francesca Trojsi, Gioacchino Tedeschi, Antonio Russo
INTRODUCTION: Although the landscape of migraine symptomatic treatment has been enriched by novel effective drugs, it is mandatory to critically reappraise older molecules to ascertain whether they could still represent reliable alternatives in specific endophenotypes of patients or migraine attacks. Among these, dihydroergotamine (DHE) nasal spray has been shown to be effective and is characterized by greater tolerability and manageability than the parenteral DHE formulation. AREAS COVERED: In this narrative review, the authors describe the pharmacodynamic and pharmacokinetic properties of DHE nasal spray and explore the results of the trials which explored its efficacy, safety and tolerability as migraine symptomatic treatment...
April 24, 2024: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38591819/what-role-can-function-magnetic-resonance-imaging-fmri-have-in-guiding-therapy-for-depression
#20
EDITORIAL
Drozdstoy S Stoyanov
No abstract text is available yet for this article.
April 9, 2024: Expert Review of Neurotherapeutics
journal
journal
39882
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.